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ABSTRACT 33 
 34 
Background 35 
 36 
Asthma in the elderly as well as asthma of adult-onset has been associated with increased 37 
morbidity, but little is known specifically about the effects of age on clinical and inflammatory 38 
outcomes in severe refractory asthma. The aims of the study were to examine the effects of 39 
age [<65 versus ≥65 years] and age of onset of asthma [childhood-onset, <18 versus adult-40 
onset, ≥18 years] on clinical and inflammatory variables in patients with severe asthma. 41 
 42 
Methods 43 
 44 
In 1042 subjects with refractory asthma recruited to the British Thoracic Society Severe 45 
Asthma Registry, we compared patient demographics, disease characteristics and biomarkers 46 
of inflammation in patients aged <65 years (n=896) versus ≥65 years (n=146) and onset at age 47 
<18 years (n=430) versus ≥18 years (n=526).  48 
 49 
Results 50 
 51 
Severe asthma patients aged ≥65 years had improved symptom control, better asthma quality 52 
of life and in the last year, less emergency visits and rescue oral steroid courses [3 (1-6) versus 53 
5 (2-7), p<0.001] than severe asthmatics aged <65 years.  Blood eosinophils were lower in the 54 
elderly group.  Patients with severe adult-onset asthma had similar symptom control, lung 55 
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function and health-care utilisation compared to severe childhood-onset asthma.  Adult-onset 56 
asthmatics had higher blood eosinophils and were less atopic. 57 
 58 
Conclusions 59 
 60 
Patients with severe refractory asthma aged ≥65 years exhibit better clinical and health care 61 
outcomes and have lower blood eosinophils compared to those aged <65 years.  Severe 62 
refractory adult-onset asthma is associated with similar levels of asthma control, higher blood 63 
eosinophils and less atopy than severe refractory childhood-onset asthma. 64 
 65 
Word count:  249 words  66 
 67 
Key words: Asthma; Adult-onset; Asthma duration; Childhood-onset; Elderly; Inflammatory 68 
biomarker. 69 
 70 
Abbreviations  71 
 72 
ACQ: Asthma control questionnaire 73 
AQLQ: Asthma quality of life questionnaire 74 
ATS: American Thoracic Society 75 
BMI: Body mass index 76 
BTS: British Thoracic Society 77 
CAP: IgE antibody enzyme-immunoassay 78 
ERS: European Respiratory Society  79 
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EuroQoL: European Quality of Life 80 
FENO50: Fraction of expired nitric oxide 50ml/s 81 
FEV1: Forced expiratory volume in one second 82 
FVC: forced vital capacity 83 
GORD: gastro-oesophageal reflux disease 84 
HAD: Hospital Anxiety and Depression 85 
ICS: Inhaled corticosteroid 86 
IL: Interleukin 87 
ITU: Intensive Therapy Unit 88 
Kco: Transfer coefficient of the lung 89 
LABA: Long-acting beta2-agonist 90 
RV: Residual volume 91 
SABA: Short acting beta2-agonist 92 
SARP: American Severe Asthma Research Programme 93 
TLC: Total lung capacity 94 
VAS: Visual analogue scale 95 
96 
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INTRODUCTION 97 
 98 
Severe refractory asthma affects all age-groups 1-3.  The prevalence of asthma in the elderly 99 
ranges from 7% to 11% 4-6, and with the expected increase in the proportion of elderly people 100 
in the population worldwide 4, 5, 7, understanding the phenotype of asthma in the elderly will 101 
be of great importance.  Asthma in older people is believed to be under-diagnosed, under-102 
treated and often associated with worse health care outcomes5, 8-11.    Co-morbid conditions, 103 
the psychosocial effects of ageing and reduced perception of bronchoconstriction 12 as well as 104 
altered airway inflammation 8, 13, 14 may contribute to worse clinical outcomes in elderly 105 
asthmatics 8, 9.   106 
 107 
To date however, there is limited information on clinical and physiological outcomes and 108 
immunological biomarkers of inflammation in older people (aged > 65 years) with severe 109 
refractory asthma compared with younger patients (aged < 65 years) with severe disease 15. In 110 
patients recruited to the American Severe Asthma Research Programme (SARP) the probability 111 
of severe disease increased with each  year of life until the age of 45 years and thereafter 112 
increased at a slower rate 16.  Clinical research trials, especially phase 2 studies, frequently 113 
exclude subjects aged >65 years 14.  It is important to know whether clinical and inflammatory 114 
variables in this group differ from younger patients when utilising new therapies for severe 115 
asthma. 116 
 117 
Age of asthma onset within the general adult asthma population can affect clinical and 118 
inflammatory variables 17, 18.  Early-onset adult asthma is associated with poor symptom 119 
control and atopy 18, 19, whereas adult-onset asthma is associated with female gender, current 120 
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smoking and greater airflow obstruction  18.  Severe adult-onset asthma may be a distinct 121 
phenotype compared to milder forms of adult-onset asthma 20 as it is associated with a 122 
greater proportion of non-atopics, worse nasal symptoms, and higher levels of inflammatory 123 
biomarkers such as exhaled nitric oxide, blood neutrophils and sputum eosinophils 20.  Adults 124 
with early-onset severe asthma have more allergic symptoms, greater allergen sensitivity and 125 
less lung eosinophilia than people with severe late-onset asthma 21.  A systematic review of 126 
four studies of adults with severe early-onset and late-onset asthma, with sample sizes 127 
ranging from 74 to 275 subjects, identified few phenotypic differences due to age of onset 18. 128 
 129 
The British Thoracic Society (BTS) Difficult Asthma Network developed a National Registry for 130 
dedicated UK Difficult Asthma Services 3.  We analysed this Registry population to examine the 131 
effects of age [<65 versus ≥65 years] and age of onset of asthma [childhood-onset, <18 versus 132 
adult-onset, ≥18 years] on clinical and inflammatory variables in 1042 patients with severe 133 
refractory asthma. 134 
 135 
METHODS 136 
 137 
Study design 138 
 139 
All subjects with refractory asthma ≥18 years old from the BTS Severe Asthma Registry were 140 
included in the analysis. The definition of refractory asthma was based on the American 141 
Thoracic Society (ATS) Criteria 22 and International European Respiratory Society (ERS)/ATS 142 
guidelines on definition, evaluation and treatment of severe asthma 23. The Registry included 143 
seven specialised asthma centres in the United Kingdom using established, dedicated 144 
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assessment protocols, to ensure identification of patients with well-characterised refractory 145 
asthma and data was collected at the time of referral to the centre. Subjects provide fully 146 
informed written consent for their data to be held in the registry. The Northern Ireland 147 
Research Ethics Committee approved research analysis of the data. To analyse the effects of 148 
age, the cohort was divided into those ≥65 years and compared with those <65 years of age. 149 
For effects of age of onset of asthma, the cohort was divided into childhood-onset of asthma, 150 
if asthma symptoms started before the age of 18 years and adult-onset, if symptoms of 151 
asthma occurred from the age of 18 onwards 20. 152 
 153 
Assessments 154 
 155 
As described previously 3, patients at all centres undergo a systematic assessment, which 156 
includes a medical history, asthma-specific questionnaires (Asthma Control Questionnaire 157 
[ACQ] scores 24; Asthma Quality of Life Questionnaire [AQLQ] scores 25); European Quality of 158 
Life [EuroQoL] health scale; and Hospital Anxiety and Depression [HAD] scores. Measurements 159 
include spirometry, static lung volumes, transfer coefficient [KCO], induced sputum cell 160 
counts, fraction of expired nitric oxide (50 mL/s [FENO50]); atopy assessment (skin prick tests, 161 
serum IgE antibody assays); blood eosinophil counts; serum total IgE concentrations and dual-162 
energy X-ray absorptiometry [DXA] scans. The tests were not performed using identical 163 
equipment across the sites because these data were collected from hospital outpatient clinics 164 
and not in the setting of a research trial. Atopy was defined as any positive immediate, 15-165 
minute, skin prick test wheal response of 3 mm larger than that elicited by the negative 166 
control or an in vitro IgE antibody serologic test (ImmunoCAP test or equivalent [>0.35 kU/L]) 167 
to common inhalant allergens. 168 
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 169 
Statistical analysis  170 
 171 
Data were analysed using statistical software (Minitab Ltd., Coventry, UK and Med Calc) and 172 
continuous variables were summarised as mean [standard deviation] or median (inter-quartile 173 
range) depending on Gaussian or skewed distribution respectively.  Their comparison, 174 
between different age categories, was by Student’s t-test and Mann-Whitney U-tests.  175 
Categorical variables were summarised by their observed frequencies and percent within the 176 
participant subsets, and were compared using χ2 test.  Age-dependent co-variates and 177 
associated p-values were determined using one-way analysis of variance (ANOVA) between 178 
patients with <65 and ≥65 years of age (MedCalc v13.2.0, Ostend, Belgium). All analyses were 179 
considered descriptive or exploratory therefore a p-value less than 5% was considered 180 
significant.   181 
 182 
RESULTS 183 
 184 
1042 subjects with refractory asthma entered in the BTS Severe Asthma Registry were 185 
included in the analyses (Table E1, Online Supplement). Age was normally distributed [mean 186 
(SD) 49.3 (14.1) years]. Sixty-five percent of the total group were female. 187 
 188 
Severe asthma patients aged ≥65 years compared with those aged <65 years  189 
 190 
Comparison of demography, clinical and inflammatory characteristics in patients aged <65 191 
years (n=896) with those aged ≥65 years (n=146) is shown in Table 1. 192 
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Demography:  In subjects with refractory asthma aged ≥ 65 years, there was a difference in 193 
smoking patterns, with a lower proportion of current smokers (2.1% versus 10.8%) and a 194 
higher proportion of ex-smokers (40.7% versus 25.7%) compared with the group aged <65 195 
years.  196 
Clinical characteristics:  The elderly group had a later age of onset of asthma and a longer 197 
duration of asthma. The older group administered slightly lower doses of inhaled 198 
corticosteroid and fewer rescue SABA puffs. ACQ and AQLQ scores were better in the older 199 
population [2.9 (2.0, 3.6) versus 3.4 (2.3, 4.3), p=0.006 and 3.79 (2.93, 4.85) versus 3.32 (2.54, 200 
4.31), p=0.005 respectively]. In the previous year, elderly patients had less unscheduled 201 
emergency visits for asthma [3 (1, 5) versus 4 (2, 6), p=0.002], less rescue oral steroid courses, 202 
[3 (1, 6) versus 5 (2, 7), p<0.001] and fewer hospital admissions for asthma [0.91 [1.59] versus 203 
1.42 [2.52], p=0.024]. FEV1% predicted levels were similar, but bronchodilator reversibility [8.5 204 
(2.4, 20.7) versus 14.1 (5.1, 27.6), p=0.009) and the ratio of FEV1/FVC post bronchodilator was 205 
lower in those above 65 years of age [63.5 (52, 70) versus 68 (57, 77), p=0.001]. A greater 206 
proportion of the elderly group had a history of cardiac disease (not including hypertension) 207 
[20.7% versus 4.5%, p<0.001) and a smaller proportion had a history of perennial rhinitis 208 
[23.2% versus 37.7%, p=0.001]. Femoral neck bone density was lower in the older group [T-209 
score -1.1 (-1.7, 0.1) versus -0.2 (-1, 0.6), p<0.001]; the difference in spinal bone density 210 
showed a trend to be worse in elderly patients (p=0.062).  211 
Biomarkers of inflammation:  FENO50 and the proportion of sputum eosinophils and neutrophils 212 
were similar in both groups, but blood eosinophils were lower in the elderly group [0.20 (0.10, 213 
0.41) versus 0.29 (0.12, 0.56) x109, p=0.014]. There was no difference in numbers of atopic 214 
individuals in both groups. 215 
 216 
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Severe asthma patients with age of onset < 18 years (childhood-onset) compared with those 217 
aged ≥ 18 years (adult-onset) 218 
 219 
Comparison of demography, clinical and inflammatory characteristics in patients with onset of 220 
asthma at age <18 (n=430) and ≥ 18 years (n=526) is shown in Table 2. 221 
Demography:  Adult-onset asthmatics compared to childhood-onset asthmatics had a slightly 222 
higher BMI and lower proportion of never-smokers. The proportion of current smokers was 223 
similar in both groups (9.1% and 9.7% respectively), although childhood-onset asthmatics had 224 
a lower pack-year smoking history. 225 
Clinical characteristics:  Adult-onset asthmatics compared to childhood-onset asthmatics had a 226 
shorter duration of asthma (16 years versus 36 years, p<0.001). The adult-onset group 227 
administered slightly lower doses of inhaled corticosteroid and fewer rescue SABA puffs and 228 
had a similar oral steroid maintenance dose. ACQ, AQLQ, lung function, rescue oral steroid 229 
courses and hospital admissions were similar in both groups, whereas total number of ITU 230 
admissions in the past year was higher in those with childhood-onset asthma (0.58 [1.60] 231 
versus 0.30 [1.32], p<0.001). A greater proportion of the adult-onset group had a history of 232 
cardiac disease (not including hypertension) [9.3% versus 4.7%, p=0.008) and a history of nasal 233 
polyps [18.2% versus 9.5%, p=0.001] and a smaller proportion had a history of perennial 234 
rhinitis [31.2% versus 39.9%, p=0.006]. Spinal and femoral bone density did not show a 235 
difference in the two groups. 236 
Biomarkers of inflammation:  Adult-onset asthmatics had higher FENO50 [35.0 (17.7, 66.3) 237 
versus 26.3 (13.9, 49.1) ppb, p=0.002], higher blood eosinophils [0.3 (0.12, 0.6) versus 0.25 238 
(0.1, 0.51) x109/L, p=0.040] and similar sputum leukocyte proportions compared to childhood-239 
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onset asthma. Adult-onset asthmatics were significantly less atopic [64.4% versus 84.7%, 240 
p<0.001], and had lower total IgE concentrations. 241 
 242 
DISCUSSION 243 
 244 
In 1042 adults with refractory asthma recruited to the UK BTS Severe Asthma Registry we 245 
investigated the effects of age and age of asthma onset on clinical characteristics and 246 
biomarkers of inflammation in sub-groups of people with severe asthma who were elderly 247 
(aged ≥65 years) or under 65 years of age and who had adult-onset or childhood-onset 248 
asthma.  Definitions of elderly asthma vary in the literature, but the commonly accepted cut-249 
off is 65 years of age 6, 7 as it combines chronological and socio-cultural dimensions.  To define 250 
childhood-onset asthma and adult-onset asthma, we chose a cut-off age of 18 years, as it is 251 
the commonly accepted age of the start of adulthood and streamlines with recent publications 252 
on severe adult-onset asthma 17, 20.   253 
 254 
Asthma in the elderly is associated with worse health care outcomes 5, 8, 9, although previous 255 
studies have not investigated clinical and inflammatory outcomes in elderly patients with 256 
severe disease.  Contrary to the published evidence that ageing might worsen asthma in the 257 
general population, we found that patients with severe refractory asthma above the age of 65 258 
years had better asthma control than adults aged <65 years with severe asthma, as assessed 259 
by lower ACQ, improved asthma quality of life and less oral steroid courses, as well as reduced 260 
unscheduled emergency visits and fewer hospitalisations.  Our data do not explain the 261 
improved clinical and health care outcome in the elderly group, although there are several 262 
possible factors that should be considered.  There were differences in smoking status between 263 
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the groups, with a lower number of current smokers and a higher proportion of ex-smokers in 264 
the group aged ≥65 years.  The higher proportion of current smokers in the younger patients 265 
may explain their increased morbidity from asthma, since smokers with severe asthma exhibit 266 
worse clinical and health-care outcomes compared with ex-smokers and never smokers with 267 
severe asthma 26, 27.  The elderly patients were not prescribed more treatment for asthma 268 
compared with the younger group, as the latter group received slightly higher daily doses of 269 
inhaled and oral corticosteroid. Non-adherence with medications occurs commonly in the 270 
elderly 28, although a survey of a large population of patients with Type 2 diabetes mellitus 271 
reported that the 18-64 year age group had poorer medication adherence than the >65 year 272 
age group 29. Whether better adherence to medication occurs in an elderly severe asthma 273 
population is not known.  Co-morbid conditions such as depression may adversely influence 274 
asthma control in the elderly with mild to moderate asthma 30, but in our study anxiety and 275 
depression scores were similar between the elderly and younger groups with severe asthma.  .  276 
Perennial rhinitis was less common in the group >65 years, although still present in nearly a 277 
quarter of elderly patients 4.  .  As expected, the elderly group had a reduced ratio of FEV1/FVC 278 
post-bronchodilator 8, 31, less reversibility to bronchodilators 32, 33  and a lower femoral neck 279 
bone density.   280 
 281 
Blood eosinophils were lower in the elderly group with severe asthma.  Mathur and colleagues 282 
34 also reported lower blood eosinophils, with no difference in sputum eosinophils, in an older 283 
group of asthmatics aged 55-80 years compared to a younger group aged 20-40 years.  The 284 
‘effector’ functions of eosinophils, such as eosinophil degranulation in response to interleukin-285 
5 stimulation was decreased in the older population 34.  Several inflammatory phenotypes are 286 
found in patients with severe asthma, which have been identified mainly on the basis of 287 
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induced sputum cell profiles in patients aged predominantly younger than 65 years35, 36.  We 288 
found that elderly patients with severe asthma had similar sputum eosinophils, sputum 289 
neutrophils and exhaled nitric oxide measurements compared with younger patients with 290 
severe asthma.  Airway neutrophilia has been associated with ageing in a population of 291 
healthy subjects and patients with asthma that included a high proportion (29.2%) of smokers 292 
in the older asthmatic group37.  The lower proportion of current smokers in the severe 293 
asthmatic group in our study may in part explain why the sputum neutrophil count was not 294 
increased in the elderly patients. In keeping with our findings, a previous report noted similar 295 
sputum neutrophil counts in elderly patients with severe asthma (>60 years) compared to 296 
younger adults 38.  Atopy levels were similar in the elderly and younger severe asthma groups. 297 
Further research is indicated to investigate factors accounting for the better clinical outcomes 298 
found in the older severe asthma group, including whether this due to altered airway 299 
inflammatory processes in the elderly. The spectrum of inflammatory variables in elderly 300 
patients with severe asthma suggests that this group should be considered eligible for clinical 301 
trials of targeted biological therapies.  302 
 303 
Severe adult-onset asthma is reported to be associated with a greater proportion of non-304 
atopics, more severe disease and lower lung function, whereas childhood-onset asthma is 305 
often associated with atopy and a good prognosis 17, 39.  There is limited information about 306 
whether the clinical characteristics in severe late-onset asthma are similar to adults with 307 
severe early-onset asthma.  A comparison of adults with severe childhood-onset asthma 308 
(n=87) with severe adult-onset asthma (n=63) reported that adult-onset patients had a shorter 309 
duration of asthma and were receiving a lower dose of inhaled corticosteroid, but that the two 310 
groups had similar impairment in lung function, requirements for oral corticosteroids and 311 
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responsiveness to corticosteroids in vitro 40.  Adults with severe asthma that first developed 312 
before age 12 years have more allergic symptoms, higher levels of atopy and less lung 313 
eosinophilia than people with severe late-onset asthma 21. A systematic review of four studies 314 
comparing severe early- and late-onset asthma in adults, identified  few phenotypic 315 
differences due to age of asthma onset 18. In a large population of patients with severe asthma 316 
we confirmed that adult-onset asthmatics (onset ≥ 18 years, n=430) compared to adults with 317 
childhood-onset asthma (n=526) had a shorter duration of asthma, received slightly lower 318 
doses of inhaled corticosteroids and had similar lung function and requirements for oral 319 
corticosteroids.  In addition, the adult-onset group had a higher proportion with a history of 320 
nasal polyps and similar symptom control, health care utilisation and number of current 321 
smokers compared to severe childhood-onset asthma.  Taken together, these findings suggest 322 
that despite the shorter duration of disease, adults with severe adult-onset asthma compared 323 
to adults with severe early-onset asthma have similar clinical characteristics, except that the 324 
adult-onset group are more likely to have nasal polyps.   325 
 326 
Inflammatory biomarkers differed between adult-onset and childhood-onset severe asthma.  327 
The adult-onset group had higher blood eosinophils and higher FENO50 levels but similar 328 
sputum cell counts.  In addition, the late-onset asthmatics were less atopic and had lower total 329 
IgE concentrations in keeping with a previous report 40.  A study of severe adult-onset asthma 330 
reported higher FENO50, higher blood neutrophils, higher sputum eosinophils and less atopy 331 
compared to mild asthma 20. The FENO50 levels were similar to our patient group, but induced 332 
sputum neutrophils and eosinophils counts were lower, possibly because of higher doses of 333 
inhaled corticosteroids suppressing eosinophils in our patient group.  Taken together, these 334 
finding suggest that patients with adult-onset severe asthma have elevated FENO50 levels and 335 
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are less atopic. In addition, they are more likely to have a blood eosinophilia compared to 336 
childhood-onset severe asthma. 337 
 338 
Major strengths of the study were that over a thousand patients with severe asthma were 339 
included in the analyses and these patients had all undergone a systematic assessment 340 
protocol to ensure identification of patients with well-characterised refractory asthma.  We 341 
recognise that there are limitations in this study, in part due to undertaking a retrospective 342 
study on registry data.  Recall bias may influence the accuracy of some clinical outcomes such 343 
as age of onset of asthma, duration of disease and frequency of health care utilization. There 344 
was incomplete data for some outcome measures including sputum cytology; however, 345 
sputum induction was performed in a similar proportion of elderly versus younger patients (38 346 
out of 146 versus 179 out of 896, chi-sq=2.8, p=0.095) and thus representative of each group, 347 
whereas a lower proportion in the adult-onset versus childhood-onset groups (70 out of 430 348 
versus 134 out of 526, chi-sq=13.0, p<0.001).  The tests, such as spirometry, lung volumes and 349 
bone density, although standardized, were performed using different equipment across the 350 
sites, as this data was collected from outpatient clinics and not in the setting of a research 351 
trial.   352 
 353 
In conclusion, we have demonstrated that elderly patients with severe refractory asthma 354 
exhibit better clinical and health care outcomes and lower peripheral blood eosinophil counts 355 
compared to those aged <65 years with severe disease, although the older patient group still 356 
experience considerable morbidity due to asthma. Patients with severe adult-onset asthma 357 
had similar outcomes for a range of clinical and health care variables compared to severe 358 
childhood-onset asthma, but had raised blood eosinophils counts and were less atopic.  Future 359 
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studies should include investigation of the pathogenic mechanisms in severe asthma in the 360 
elderly and in severe adult-onset asthma as well as identifying target therapies for these 361 
populations that have poorly controlled disease. 362 
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Table 1:  Demography, clinical and inflammatory characteristics in patients with severe asthma  
aged <65 years compared with those aged ≥65 years 
 
Variable <65 years of age n ≥ 65 years of age n p value 
Demography      
Age, yrs 48 [39-55] 896 69 [66-74] 146  
Gender, Female : Male 594 : 302 896 86 : 60 146 0.085 
Body mass index, Kg/m2 29.8 [25.2-34.4] 871 28.5 [25.5-32.0] 143 0.069 
Smoking status, never : ex : current, % 63.3 : 25.7 : 10.8 863 57.1 : 40.7 : 2.1 140 <0.001 
Pack years smoked (current/ex-smokers) 13.0 [5.0-26.0] 263 8.0 [5.0-30.0] 55 0.737 
Clinical characteristics       
Asthma history      
Age at onset of asthma symptoms, yrs 17 [3-34] 851 41 [16-57] 139 <0.001 
Duration of asthma, yrs 24 [13-36] 850 29 [14-55] 142 0.001 
Medication use      
ICS dose, beclometasone equivalent, mcg [Mean (SD)] 2087.7 [1298.2]  856 1741.3 [830.1] 
 
137 0.001 
Rescue SABA, puffs/day   8 [4-10] 672 6 [4-8] 107 0.001 
Leukotriene receptor antagonists, yes [%] 471 [53.2%] 886 61 [42%] 145 0.013 
Anti-IgE treatment, yes [%] 26 [3.0%] 876 0 [0%] 45 0.036 
On daily oral steroids, yes [%] 363 [41%] 888 57 [39%] 146 0.675 
Daily oral steroid dose, mg 15.0 [10.0-25.0] 354 10.0 [7.1-20.0] 56 0.040 
Asthma and generic questionnaire scores      
ACQ Score 3.4 [2.3-4.3] 411 2.9 [2.0-3.60] 51 0.006 
AQLQ Total Score 3.32 [2.54-4.31] 533 3.79 [2.93-4.85] 70 0.005 
Euroqol VAS Scale 50 [35-70] 464 57 [39-71] 58 0.607 
Anxiety Score 9.0 [4.7-13.0] 610 8.0 [4.0-12.0] 85 0.175 
Depression Score 7.0 [3.0-10.0] 608 6.0 [3.0-9.0] 85 0.144 
Exacerbations and health care utilization      
Rescue steroid courses in the past year 5.0 [2.0-7.0] 757 3.0 [1.0-6.0] 123 <0.001 
Unscheduled GP/emergency visits in past yr 4.0 [2.0-6.0] 803 3.0 [1.0-5.0] 132 0.002 
Total number of ITU admissions [Mean (SD)] 0.48 [1.54]  
 
854 0.28 [0.83]  
 
137 0.194 
Hospital admissions in past yr [Mean (SD)] 1.42 [2.52] 
 
858 0.91 [1.59] 
 
137 0.024 
Lung function      
Pre-bronchodilator FEV1%predicted 71.0 [52.0-89.0] 811 70.0 [50.3-83.0] 136 0.377 
Post-bronchodilator FEV1/FVC  68.0 [57.3-77.0] 528 63.5 [52.0-70.0] 88 0.001 
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FEV1 reversibility 14.1 (5.1, 27.6) 508 8.5 (2.4, 20.7) 89  0.009 
Residual Volume % predicted 124 [96-154] 483 117 [99-141] 79 0.531 
Kco % predicted 101 [90-113] 570 98 [86-111] 91 0.088 
Co-morbidities      
Cardiac disease (not including hypertension), yes [%]  40 [4.5%] 892 30 [20.7%] 145 <0.001 
Diabetes, yes [%] 36 [4.2%] 860 9 [6.6%] 137 0.264 
GORD, yes [%] 466 [52.8%] 882 73 [51.4%] 142 0.752 
History of perennial rhinitis, yes [%] 333 [37.7%] 883 33 [23.2%] 142 0.001 
History of nasal polyps, yes [%] 120 [13.8%] 871 20 [14.2%] 141 0.897 
Bone density      
Spinal Bone Density T-score -0.60 [-1.60- 0.29] 329 -1.20 [-2.10- 0.10] 63 0.062 
Femoral neck bone density T-score -0.20 [-1.00- 0.60] 323 -1.10 [-1.70- 0.10] 63 <0.001 
Biomarkers of inflammation      
Exhaled nitric oxide, FENO50 ppb 29.9 [13.4-58.0] 454 28.0 [16.8-49.0] 49 0.936 
Eosinophil count in blood, x109/L 0.29 [0.12-0.56] 809 0.20 [0.10-0.41] 138 0.014 
Eosinophils in sputum, % 2.7 [0.4-9.6] 179 2.6 [0.5-13.5] 38 0.564 
Neutrophils in sputum, % 50 [22-73] 149 36 [19-59] 35 0.168 
Total IgE, Ku/L 149 [44-440] 819 134 [44-336] 128 0.386 
Atopic, n (%) 534 [76.0%] 703 55 [67.9%] 81 0.112 
 
n=Data points, median [IQR] unless stated otherwise. 
 
*Atopy: defined as serum IgE antibody positive to any of house dust mite, grass pollen 
or cat allergens measured by skin prick test or by enzyme-immunoassay. CAP positive 
is IgE antibody titre ≥0.35u/ml, and skin prick test positive is weal diameter >3mm. 
 
Abbreviations: ACQ: Asthma control questionnaire; AQLQ: Asthma quality of life 
questionnaire; EuroQoL: European Quality of Life; FENO50: Fraction of expired nitric 
oxide 50ml/s; GORD: gastro-oesophageal reflux disease; GP: general practitioner; 
HAD: Hospital Anxiety and Depression; ICS: Inhaled corticosteroid; IgE: 
Immunoglobulin E; ITU: Intensive Therapy Unit; Kco: transfer coefficient; CAP: IgE 
antibody enzyme-immunoassay; RV: Residual volume; SABA: short acting beta2-
agonist; VAS=visual analogue scale. 
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Table 2: Demography, clinical and inflammatory characteristics in childhood-onset asthma 
(onset < 18 years of age) compared with adult-onset refractory asthma (> 18 years) 
 
Variable 
 
Onset of asthma 
at < 18 years 
n 
 
Onset of asthma 
at  ≥ 18 years 
n p value 
Demography      
Age, years 44 [31-54] 430 55 [48-62] 526 <0.001 
Gender, Female : Male  % 67.2 : 32.8 430 63.1 : 36.9 526 0.187 
Body mass index, Kg/m2  29.0 [24.7-33.2] 418 30.1 [25.7-34.9] 516 0.003 
Smoking status never : ex : current % 69.8 :20.4: 9.7 411 56.4 : 34.6 : 9.1 518 <0.001 
Pack years smoked (current/ex-smokers) 9.50 [4.0-20.0] 96 15.0 [5.0-30.0] 200 0.010 
Clinical characteristics      
Asthma history      
Age at onset of asthma symptoms, yrs 4.0 [2.0- 10.2] 430 36.5 [27.0- 45.0] 526 <0.001 
Duration of asthma, yrs 36 [26-48] 429 16 [9-25] 526 <0.001 
Medication use      
ICS [beclometasone equivalent], mcg [Mean (SD)] 2158.7 [1500.9]  405 1954.0 [1029.0]  505 0.012 
Average rescue SABA puffs/day   8 [4-12] 328 6 [4-10] 387 <0.001 
Leukotriene receptor antagonists, yes [%]  218 [51%] 424 257 [49%] 522 0.505 
Anti-IgE treatment, yes [%] 12 [3%] 422 11 [2%] 519 0.474 
Maintenance oral steroids, yes [%]   164 [38%] 427 221 [42%] 521 0.211 
Maintenance oral steroid dose, mg 15.0 [10.0-30.0] 159 15.0 [10.0-20.0] 216 0.055 
Asthma and generic questionnaire scores       
ACQ Score 3.30 [2.20-4.13] 190 3.30 [2.30-4.10] 215 0.852 
AQLQ Total Score 3.45 [2.62-4.49] 253 3.31 [2.50-4.35] 299 0.301 
Euroqol VAS Scale 55.0 [37.0-70.0] 219 50.0 [35.0-70.0] 261 0.364 
HAD Anxiety Score 8.0 [4.0-12.0] 280 9.0 [5.0-13.0] 350 0.173 
HAD Depression Score 6.0 [3.0-10.0] 280 7.0 [4.0-10.0] 348 0.027 
Exacerbations and health care utilization      
Rescue oral steroid courses in the past yr 4.0 [2.0-6.0] 367 4.0 [2.0-7.0] 449 0.301 
Unscheduled GP/emergency visits in past yr 4.0 [2.0-6.0] 398 4.0 [2.0-6.0] 482 0.523 
Total number of ITU admissions [Mean (SD)] 0.58 [1.60] 
 
412 0.30 [1.32] 
 
505 <0.001 
Hospital admissions in past yr [Mean (SD)] 1.37 [2.35] 
 
414 1.26 [2.21] 
 
508 0.909 
Lung function      
FEV1 Pre-bronchodilator, % predicted 72.0 [ 50.0-88.0] 382 70.0 [52.0-87.0] 490 0.447 
Post-bronchodilator FEV1/FVC  68.0 [55.0-76.0] 239 67.0 [55.0-5.3] 322 0.586 
FEV1 reversibility 11.7 [3.5, 25.5] 225 14.5 [5.5, 29.1] 318 0.088  
Residual volume, % predicted 124 [97-152] 242 122 [97-150] 293 0.839 
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Kco % predicted 101 [91-112] 283 101 [88-113] 329 0.467 
Co-morbidities      
Cardiac disease (not including hypertension), yes [%] 20 [4.7%] 429 48 [9.3%] 514 0.008 
Diabetes, yes [%] 13 [3.2%] 417 27 [5.4%] 499 0.105 
GORD, yes [%] 212 [50.2%] 422 283 [54.4%] 520 0.201 
History of perennial rhinitis, yes (%) 169 [39.9%] 424 162 [31.2%] 519 0.006 
History of nasal polyps, yes (%) 40 [9.5%] 420 94 [18.2%] 515 <0.001 
Bone density      
Spinal Bone Density, T-score -2.0 [-0.7- 0.30] 143 -0.60 [-1.60- 0.23] 228 0.245 
Femoral neck bone density, T-score -1.22 [-0.5- 0.50] 141 -1.13 [-0.20- 0.50] 226 0.209 
Biomarkers of inflammation      
Exhaled nitric oxide, FENO50 ppb 26.3 [13.9-49.1] 210 35.0 [17.0-66.3] 242 0.002 
Eosinophil count in blood, x109/L 0.25 [0.1-0.51] 393 0.30 [0.12-0.60] 476 0.040 
Eosinophils in sputum, % 1.73 [0.19-6.4] 70 3.50 [0.50-13.96] 134 0.077 
Neutrophils in sputum, % 44.5 [18.8-67.5] 59 49.8 [26.1-72.6] 114 0.239 
Total IgE, Ku/l  240 [53-629] 391 113 [41-295] 479 <0.001 
Atopic*, n (%) 300 [84.7%] 354 230 [64.4%] 357 <0.001 
 
Data depicted as median [IQR], unless specified. 
 
*Atopy defined as serum IgE antibody positive to any of house dust mite, grass pollen or cat 
allergens measured by skin prick test or by enzyme-immunoassay. CAP positive is IgE antibody titre 
≥0.35u/ml, and skin prick test positive is weal diameter >3mm. 
 
Abbreviations: ACQ: Asthma control questionnaire; AQLQ: Asthma quality of life questionnaire; EuroQoL: 
European Quality of Life; FENO50: Fraction of expired nitric oxide 50ml/s; FEV1: forced expired volume in 
the first minute; GORD: gastro-oesophageal reflux disease; GP: general practitioner; HAD: Hospital 
Anxiety and Depression; ICS: Inhaled corticosteroid; IgE: Immunoglobulin E; ITU: Intensive Therapy Unit; 
Kco: transfer coefficient; CAP: IgE antibody enzyme-immunoassay; RV: Residual volume; SABA: short 
acting beta2-agonist; VAS: visual analogue scale 
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 Table E1: Demography, clinical and inflammatory characteristics in all patients with 
severe asthma  
 
 
Variable All subjects n 
Demography   
Age, yrs; mean (SD) 49.3 (14.1) 1042 
Gender, Female : Male 680 : 362 1042 
Body mass index, Kg/m2 29.6 [25.4-34.1] 1014 
Smoking status, never : ex : current, % 62.5 : 27.8 : 9.7 1003 
Pack years smoked (current/ex-smokers) 12.0 [5.0-27.8] 318 
Clinical characteristics    
Asthma history   
Age at onset of asthma symptoms, yrs 20 [4-38] 990 
Duration of asthma, yrs 25 [14-38] 992 
Medication use   
ICS dose, beclometasone equivalent, mcg [Mean (SD)] 2040 (1250)     
 
993 
Rescue SABA, puffs/day   8 [4-10] 779 
Leukotriene receptor antagonists, yes [%] 532 [51.6%] 1031 
Anti-IgE treatment, yes [%] 26 [2.5%] 1021 
On daily oral steroids, yes [%] 420 [41%] 1034 
Daily oral steroid dose, mg 15 [10-23] 410 
Asthma and generic questionnaire scores   
ACQ Score 3.3 [2.3-4.1] 462 
AQLQ Total Score 3.38 [2.57-4.37] 603 
Euroqol VAS Scale 50 [36-70] 522 
Anxiety Score 9.0 [4.0-12.0] 695 
Depression Score 7.0 [3.0-10.0] 693 
Exacerbations and health care utilization   
Rescue steroid courses in the past year 4.0 [2.0-7.0] 880 
Unscheduled GP/emergency care visits in the past year 4.0 [2.0-6.0] 935 
Total number of ITU admissions [Mean (SD)] 0.45 (1.47)    
 
991 
Hospital admissions in past year [Mean (SD)] 1.35 (2.42) 
 
995 
Lung function   
Pre-bronchodilator FEV1%predicted 71.0 [51.0-87.0] 947 
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Post-bronchodilator FEV1/FVC  67.0 [56.0-76.0] 616 
FEV1 reversibility 13.0 [4.5, 27.0] 543 
Residual Volume % predicted 123 [97-151] 562 
Kco % predicted 101 [89-113] 661 
Co-morbidities   
Cardiac disease (not including hypertension), yes [%] 70 [6.7%] 1037 
Diabetes, yes [%] 45 [4.3%] 1042 
GORD, yes [%] 539 [52.6%] 1024 
History of perennial rhinitis, yes [%] 366 [35.7%] 1025 
History of nasal polyps, yes [%] 140 [13.8%] 1012 
Bone density   
Spinal Bone Density T-score -0.62 [-1.70-0.21] 392 
Femoral neck bone density T-score -0.30 [-1.20- 0.50] 386 
Biomarkers of inflammation   
Exhaled nitric oxide, FENO50 ppb 29.8 [14.0-58.0] 502 
Eosinophil count in blood, x109/L 0.28 [0.11-0.54] 947 
Eosinophils in sputum, % 2.7 [0.4-10.0] 217 
Neutrophils in sputum, % 47 [22-63] 184 
Total IgE, Ku/L 144 [44-433] 947 
Atopic, n (%) 589 [75.1%] 784 
 
n=Data points, median [IQR] unless stated otherwise. 
 
*Atopy: defined as serum IgE antibody positive to any of house dust mite, 
grass pollen or cat allergens measured by skin prick test or by enzyme-
immunoassay. CAP positive is IgE antibody titre ≥0.35u/ml, and skin prick 
test positive is weal diameter >3mm. 
 
Abbreviations: ACQ: Asthma control questionnaire; AQLQ: Asthma quality of 
life questionnaire; EuroQoL: European Quality of Life; FENO50: Fraction of 
expired nitric oxide 50ml/s; GORD: gastro-oesophageal reflux disease; GP: 
general practitioner; HAD: Hospital Anxiety and Depression; ICS: Inhaled 
corticosteroid; IgE: Immunoglobulin E; ITU: Intensive Therapy Unit; Kco: 
transfer coefficient; CAP: IgE antibody enzyme-immunoassay; RV: Residual 
volume; SABA: short acting beta2-agonist; VAS: visual analogue scale. 
